Varian Medical Systems (NYSE:VAR) announced today that it won FDA 510(k) clearance for its Ethos AI-driven adaptive intelligence solution for cancer care.
Ethos is designed to offer an adaptive treatment based on the patient’s anatomy and position to better target the tumor, reduce the dose to healthy tissue and improve overall outcomes within a 15-minute time slot from patient setup through treatment delivery.
Varian’s system allows for a physician to define their clinical intent from pre-defined templates and base an initial treatment plan on their predetermined clinical objectives, according to a news release. The treatment can then be adapted as a response to changes in anatomy and the tumor’s shape and position at the time of treatment.
Ethos is capable of providing multimodality images, including MR, PET and CT images, along with daily iterative CBCT images to offer clinicians ways to make their adaptive treatment decisions.
“Ethos is the long-awaited solution that puts each patient truly at the center of care,” Varian oncology systems president Chris Toth said in the news release. “With Ethos, on-couch adaptive therapy is no longer an elusive aspiration that is too complex and time-consuming to be practical and too exclusive for most clinics and patients. This is another important step in cancer care that moves us closer to achieving our vision of a world without fear of cancer.”
Varian has been available in Europe for nearly five months, having won CE Mark approval in September 2019.
